Blood thinner drugs prescribed following an acute coronary syndrome (ACS) event only work to put patients at greater risk of serious and life-threatening bleeding episodes than they do at preventing ischemic events. This study included analysis of the new and controversial blood thinner drug Pradaxa.
MedPageToday.com reports on a new meta-analysis of seven clinical studies on the effects of Xa inhibitors or direct thrombin inhibitors prescribed following ACS. The analysis found that taking these blood thinning drugs greatly increased the risk of severe bleeding episodes and didn’t really lower the risk of suffering ischemic events.
The report details the findings of the study, which are published in the most recent edition of the journal, Archives of Internal Medicine:
The bleeding risk mostly negated the significant — but modest — reduction in composite ischemic events (OR 0.86, 95% CI 0.79 to 0.94) and a nonsignificant decrease in overall deaths (OR 0.86, 95% CI 0.79 to 1.04), resulting in a net clinical benefit odds ratio of 0.98 (95% CI 0.90 to 1.06,P=0.57).